Application of carfilzomib and epirubicin combined medicine to preparation of medicine for treating liver cancer

Abstract

The invention belongs to the field of medicine, and particularly relates to an application of a carfilzomib and epirubicin combined medicine to preparation of a medicine for treating liver cancer. The application of the carfilzomib and epirubicin combined medicine to preparation of the medicine for treating the liver cancer is provided for the first time, the carfilzomib and the epirubicin have an obvious synergistic effect, the curative effect is effectively improved, the curative effect is more obvious compared with that of a single component, and the killing performance on tumor cells is improved; and the dosage is effectively reduced, so that toxic and side effects are reduced. The combined use of the carfilzomib and the epirubicin can save the cost, the economic burden of patients is reduced, a new way is provided for the prevention and treatment of the liver cancer, and the combined use of the carfilzomib and the epirubicin has wide application prospects in the field of medicine and pharmacology.

Description

technical field

[0001] The invention belongs to the field of medicine, and in particular relates to the application of carfilzomib and epirubicin in the preparation of drugs for treating liver cancer. Background technique

[0002] Liver cancer is one of the common malignant tumors in my country, which can be divided into two categories: primary and secondary. Liver cancer cells have strong proliferative ability, and tumor nodules can reach more than ten centimeters. At the same time, they are highly metastatic. They can metastasize not only in the liver, but also to extrahepatic tissues. The most common metastases are lungs, and they can also metastasize to adrenal glands, bones, and kidneys. , brain, etc. At present, the treatment methods for liver cancer are still based on surgery, radiotherapy, and chemotherapy, and the curative effect has not yet made breakthrough progress.

[0003] Epirubicin (Epirubicin, Epirubicin) is a representative drug among anthracycline antitu...

Examples

Embodiment 1

[0021] Example 1 MTT method to detect the sensitivity of liver cancer cells to carfilzomib and epirubicin

[0022] 1. Experimental materials

[0023] (1) Drugs: carfilzomib, epirubicin.

[0024] (2) Liver cancer cells: human liver cancer cells HEPG2.

[0025] (3) Commercially available MTT kits.

[0026] 2. Experimental grouping

[0027] (1) Carfilzomib group: different concentrations of carfilzomib were used to treat liver cancer cells.

[0028] (2) Epirubicin group: different concentrations of epirubicin were used to treat liver cancer cells.

[0029] 3. MTT method to detect the sensitivity of tumor cells to carfilzomib and epirubicin

[0030] (1) Human hepatoma cells HEPG2 were inoculated into a 96-well plate at a rate of 5000-9000 cells per well. After the cells adhered to the wall, different concentrations of carfilzomib or epirubicin in PBS were added. After culturing for 24 hours, add 10 μl of MTT with a concentration of 5 mg / ml to each well for another 4 hours, t...

Embodiment 2

[0032] Example 2 Effect of Carfilzomib and Epirubicin Combination on the Inhibition Rate of Liver Cancer Cells

[0033] 1. Experimental materials

[0034] (1) Drugs: carfilzomib, epirubicin.

[0035] (2) Liver cancer cells: human liver cancer cells HEPG2.

[0036] (3) Commercially available MTT kits.

[0037] 2. Experimental grouping

[0038] Combination of different concentrations of carfilzomib and epirubicin to treat liver cancer cells.

[0039] 3. MTT method to detect the sensitivity of liver cancer cells to the combination of carfilzomib and epirubicin

[0040] (1) Human hepatoma cells HEPG2 were inoculated into 96-well plates with 5000-9000 cells per well. After the cells adhered to the wall, PBS solutions with different ratios of carfilzomib and epirubicin were added. After culturing for 24 hours, add 10 μl of MTT with a concentration of 5 mg / ml to each well for another 4 hours, then discard the culture solution and add 100 μl of DMSO to each well, and read the abs...

Embodiment 3

[0042] Example 3 Mouse experiment

[0043] 1. Experimental materials

[0044] (1) Drugs: carfilzomib, epirubicin.

[0045] (2) Nude mice aged 4-6 weeks, weighing 18-20g / mouse, male and female.

[0046] 2. Experimental grouping

[0047] (1) Control group: without any treatment.

[0048] (2) Carfilzomib group: Carfilzomib 16 mg / kg was administered orally, once a day.

[0049] (3) Epirubicin group: Epirubicin 60 mg / kg was administered by intragastric administration, once a day.

[0050] (4) Carfilzomib and epirubicin combined group: the doses and administration methods of carfilzomib and epirubicin were the same as those of the above two groups.

[0051] 3. Administration treatment Observe the weight and volume changes of transplanted tumors in mice.

[0052] (1) HEPG2 cells were grown adherently in RPMI-1640 complete medium containing 10% fetal bovine serum at 37°C, 5% CO 2 , Routine culture in a saturated humidity incubator, and passaging once every 2-3 days. Collect an...

technical field

[0001] The invention belongs to the field of medicine, and in particular relates to the application of carfilzomib and epirubicin in the preparation of drugs for treating liver cancer. Background technique

[0002] Liver cancer is one of the common malignant tumors in my country, which can be divided into two categories: primary and secondary. Liver cancer cells have strong proliferative ability, and tumor nodules can reach more than ten centimeters. At the same time, they are highly metastatic. They can metastasize not only in the liver, but also to extrahepatic tissues. The most common metastases are lungs, and they can also metastasize to adrenal glands, bones, and kidneys. , brain, etc. At present, the treatment methods for liver cancer are still based on surgery, radiotherapy, and chemotherapy, and the curative effect has not yet made breakthrough progress.

[0003] Epirubicin (Epirubicin, Epirubicin) is a representative drug among anthracycline antitu...

Examples

Embodiment 1

[0021] Example 1 MTT method to detect the sensitivity of liver cancer cells to carfilzomib and epirubicin

[0022] 1. Experimental materials

[0023] (1) Drugs: carfilzomib, epirubicin.

[0024] (2) Liver cancer cells: human liver cancer cells HEPG2.

[0025] (3) Commercially available MTT kits.

[0026] 2. Experimental grouping

[0027] (1) Carfilzomib group: different concentrations of carfilzomib were used to treat liver cancer cells.

[0028] (2) Epirubicin group: different concentrations of epirubicin were used to treat liver cancer cells.

[0029] 3. MTT method to detect the sensitivity of tumor cells to carfilzomib and epirubicin

[0030] (1) Human hepatoma cells HEPG2 were inoculated into a 96-well plate at a rate of 5000-9000 cells per well. After the cells adhered to the wall, different concentrations of carfilzomib or epirubicin in PBS were added. After culturing for 24 hours, add 10 μl of MTT with a concentration of 5 mg / ml to each well for another 4 hours, t...

Embodiment 2

[0032] Example 2 Effect of Carfilzomib and Epirubicin Combination on the Inhibition Rate of Liver Cancer Cells

[0033] 1. Experimental materials

[0034] (1) Drugs: carfilzomib, epirubicin.

[0035] (2) Liver cancer cells: human liver cancer cells HEPG2.

[0036] (3) Commercially available MTT kits.

[0037] 2. Experimental grouping

[0038] Combination of different concentrations of carfilzomib and epirubicin to treat liver cancer cells.

[0039] 3. MTT method to detect the sensitivity of liver cancer cells to the combination of carfilzomib and epirubicin

[0040] (1) Human hepatoma cells HEPG2 were inoculated into 96-well plates with 5000-9000 cells per well. After the cells adhered to the wall, PBS solutions with different ratios of carfilzomib and epirubicin were added. After culturing for 24 hours, add 10 μl of MTT with a concentration of 5 mg / ml to each well for another 4 hours, then discard the culture solution and add 100 μl of DMSO to each well, and read the abs...

Embodiment 3

[0042] Example 3 Mouse experiment

[0043] 1. Experimental materials

[0044] (1) Drugs: carfilzomib, epirubicin.

[0045] (2) Nude mice aged 4-6 weeks, weighing 18-20g / mouse, male and female.

[0046] 2. Experimental grouping

[0047] (1) Control group: without any treatment.

[0048] (2) Carfilzomib group: Carfilzomib 16 mg / kg was administered orally, once a day.

[0049] (3) Epirubicin group: Epirubicin 60 mg / kg was administered by intragastric administration, once a day.

[0050] (4) Carfilzomib and epirubicin combined group: the doses and administration methods of carfilzomib and epirubicin were the same as those of the above two groups.

[0051] 3. Administration treatment Observe the weight and volume changes of transplanted tumors in mice.

[0052] (1) HEPG2 cells were grown adherently in RPMI-1640 complete medium containing 10% fetal bovine serum at 37°C, 5% CO 2 , Routine culture in a saturated humidity incubator, and passaging once every 2-3 days. Collect an...

Images